Ngā hua rapu - Marker, Mahtab

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study mā Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma mā Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study mā Voss, Martin H, Reising, Albert, Cheng, Yuan, Patel, Parul, Marker, Mahtab, Kuo, Fengshen, Chan, Timothy A, Choueiri, Toni K, Hsieh, James J, Hakimi, A Ari, Motzer, Robert J

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer - Data from a Randomized Phase III Trial mā Hakimi, A. Ari, Voss, Martin H., Kuo, Fengshen, Sanchez, Alejandro, Liu, Ming, Nixon, Briana, Vuong, Lynda, Ostrovnaya, Irina, Chen, Ying Bei, Reuter, Victor E., Riaz, Nadeem, Cheng, Yuan, Patel, Parul, Marker, Mahtab, Reising, Albert, Li, Ming, Chan, Timothy A., Motzer, Robert J.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib mā Syeda, Mahrukh M, Wiggins, Jennifer M, Corless, Broderick C, Long, Georgina V, Flaherty, Keith T, Schadendorf, Dirk, Nathan, Paul D, Robert, Caroline, Ribas, Antoni, Davies, Michael A, Grob, Jean Jacques, Gasal, Eduard, Squires, Matthew, Marker, Mahtab, Garrett, James, Brase, Jan C, Polsky, David

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial mā Motzer, Robert J, Porta, Camillo, Vogelzang, Nicholas J, Sternberg, Cora N, Szczylik, Cezary, Zolnierek, Jakub, Kollmannsberger, Christian, Rha, Sun Young, Bjarnason, Georg A, Melichar, Bohuslav, De Giorgi, Ugo, Gruenwald, Viktor, Davis, Ian D, Lee, Jae-Lyun, Esteban, Emilio, Urbanowitz, Gladys, Cai, Can, Squires, Matthew, Marker, Mahtab, Shi, Michael, Escudier, Bernard

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma mā Hsieh, James J., Chen, David, Wang, Patricia I., Marker, Mahtab, Redzematovic, Almedina, Chen, Ying-Bei, Selcuklu, S. Duygu, Weinhold, Nils, Bouvier, Nancy, Huberman, Kety H., Bhanot, Umesh, Chevinsky, Michael S., Patel, Parul, Pinciroli, Patrizia, Won, Helen H., You, Daoqi, Viale, Agnes, Lee, William, Hakimi, A. Ari, Berger, Michael F., Socci, Nicholas D., Cheng, Emily H., Knox, Jennifer, Voss, Martin H., Voi, Maurizio, Motzer, Robert J.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa